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ABSTRACT- PURPOSE. Comparative drug 
release kinetics from nanoparticles was carried out 
using conventional and our novel models with the 
aim of finding a general model applicable to multi 
mechanistic release. Theoretical justification for the 
two best general models was also provided for the 
first time. METHODS. Ten conventional models 
and three models developed in our laboratory were 
applied to release data of 32 drugs from 106 
nanoparticle formulations collected from literature. 
The accuracy of the models was assessed 
employing mean percent error (E) of each data set, 
overall mean percent error (OE) and number of Es 
less than 10 percent. RESULTS. Among the 
models the novel reciprocal powered time (RPT), 
Weibull (W) and log- probability (LP) ones 
produced OE values of 6.47, 6.39 and 6.77, 
respectively. The OEs of other models were higher 
than 10%. Also the number of errors less than 10% 
for the models was 84.9, 80.2 and 78.3 percents of 
total number of data sets. CONCLUSIONS. 
Considering the accuracy criteria the reciprocal 
powered time model could be suggested as a 
general model for analysis of multi mechanistic 
drug release from nanoparticles. Also W and LP 
models were the closest to the suggested model 
RPT.  
 
INTRODUCTION 
 
Nanotechnology has been received immense 
attentions in various branches of science including 
medical and pharmaceutical sciences (1). Numerous 
research articles in the field of pharmaceutical 
nanotechnology have been appeared in literature 
citation. Our focus, however, is on some recently 
published review articles that deal with 
pharmaceutical nanotechnology (2-7). The drug 
release from pharmaceutical nanoparticles is a 
major determinant in its biological effect, thus 
evaluation of drug release kinetic is of paramount 
importance in the field. The use of kinetic models is 
often helpful in elucidating release mechanisms 
which in turn can be of use in the control of drug 
release. Another advantage of the kinetics is to 
represent several release data with one or two 
parameters. To the best of our knowledge a 
comprehensive kinetic representation of drug 
release from nanoparticles for the purpose of 
finding a general model has not been reported in the 
literature. Parameters obtained from such a general 
model can be employed for comparing different 
delivery systems of a drug as well as correlating 
with bioavailability data. It is obvious that the 
comparison and correlation cannot be made with 
parameters obtained from data fitting to various 
kinetic models. In the present work release data of 
32 drugs from 106 nanoparticle formulations 
gathered from various research articles was 
analyzed using 10 well known (8,9) as well as 3 
models developed in our laboratory (10,11). Also, a 
theoretical justification of the best models is 
provided from a general rate expression describing 
both the Noyes-Whitney dissolution law as well as 
Fick’s first law of diffusion.  
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METHODS 
 
Kinetic models  
 
The  kinetic models were those which have been 
used in interpretation of drug release data (8-11). 
The equations of the kinetic models are presented in 
Table 1.  
 
Data 
 
The release data for kinetic analysis was collected 
from various research articles the list of which is 
seen in Table 2. The name of drugs, type of 
nanoparticles, number of data in each set and the 
method of release measurement are included in the 
Table.  
Table 1: Kinetic models used for analysis of drug nanoparticle release data and their corresponding overall mean percent errors 
(OE) together with their percent number of errors (NE) less than 5%, 10% and 12%.  
 
No. Model name a   Model OE  NE < 5 NE < 10 NE < 12 
1 Zero order  F=k0t 18.28  4.7 34.9 46.2 
2 First order  ln (1-F) = - kft 16.41  19.8 46.2 54.7 
3 Higuchi   10.65  28.3 65.1 68.9 
4 Power law  ln F = ln kp + plnt 7.66  32.1 53.8 56.6 
5 Hixson-Crowell  
 
26.63  9.4 25.5 32.1 
6 Square root of mass  
 
16.46  11.3 43.4 53.8 
7 Three seconds root of 
mass   
17.16  6.6 40.6 52.8 
8 Weibull  ln[-ln(1-F)]= - βln td  + βlnt 6.39  47.2 80.2 85.8 
9 Linear  probability  Z = Z0 + qt 16.67  11.3 40.6 51.9 
10 Log – probability  Z = Z0' + q'lnt 6.77  40.6 78.3 88.7 
11 Non conventional order 1 1- (1-F)1-n =(1-n) k1-nt  14.74 (n<1) 25.5 50.0 59.4 
12 Non conventional order 2 
 
11.97 (n>1) 34.0 57.5 65.1 
13 Reciprocal  powered 
time    
6.47  49.1 84.9 89.6 
 
a Parameters of models 1-10 were obtained by linear regression and those of 11-13 were calculated via nonlinear regression. F 
denotes fraction of drug released up to time t. k0, kf, kH, p, kP, k1/3,k1/2, k2/3, td, β, Z0, Z0', q, q', n, k1-n, kn-1, m and  b are parameters 
of the models. Z and  Z' are probits of fraction of drug released at any time. Z0 and Z0' are the values of Z and Z' when t = 0 and t= 
1, respectively. The relationships between Z and Z' with F are given by:  
 
 
 
Where Z = (t - t50%)/σ and Z' = (logt - logt50%)/σ'. σ and σ' are relevant standard deviations (8,64). 
 
tkF H=
‘
J Pharm Pharmaceut Sci (www. cspsCanada.org) 11 (1): 167-177, 2008 
 
 
 
 
169 
 
Methods      
 
The coordinates of each point in the release profile 
of drug nanoparticles in the original paper were 
measured carefully and the data was employed in 
the subsequent kinetic analysis. The accuracy and 
prediction ability of the models were compared by 
calculation of absolute percent error (E) for each set 
as well as overall mean percent error (OE) for all 
sets are given by equations 1 and 2: 
 
  (1) 
 
   (2) 
 
Fcal,i  and Fobs,i denote calculated fraction and 
observed fraction of drug released at the ith sample, 
respectively. The value of N is the number of data 
in each set. The number of single figure OEs 
associated with the models expressed as percentage 
of total number of sets was also employed to select 
suitable models.  
 
RESULTS  
 
The release data of all 106 formulations was fitted 
to 13 models mentioned in Table 1. The overall 
error, number of errors expressed as percentage of 
total number of sets, NEs, less than 5, 10 and 12% 
for the models are seen in the same table. The 
values of E, squared correlation coefficient (R2) and 
the parameters of reciprocal powered time model 
for the nanoparticle formulations are given in Table 
2.  
 
 
Table 2: Detail of drug nanoparticles as well as squared correlation coefficients (R2), percent error (E) and parameters of 
the Reciprocal powered time model. 
 
Reciprocal powered time model 
 No. Drug name Reference N
a Nanoparticle typeb 
R2 E m b t50% (hour)d 
1 5-fluorouridine (12) 6 NS 0.993 3.3 0.663 1.185 0.7 
2 5-fluorouridine (12) 7 NS 0.985 4.8 0.562 1.442 0.7 
3 5-fluorouridine (12) 7 NS 0.965 4.3 0.942 0.625 0.9 
4 5-fluorouridine (12) 7 NS 0.983 3.7 0.776 0.747 0.7 
5 5-fluorouridine (12) 7 NS 0.995 4.3 1.401 1.094 1.4 
6 5-fluorouridine (12) 7 NS 0.991 2.2 1.154 0.589 1.3 
7 6-coumarin (13) 10 NCP 0.996 4.4 6.629 0.643 18.9 
8 6-coumarin (13) 10 NCP 0.889 18.8 11.190 0.660 38.8 
9 9-(methylamino 
methyl)anthracene 
(14) 10 NCP 0.971 4.8 1.537 1.365 1.4 
10 9-(methylamino 
methyl)anthracene 
(14) 9 NCP 0.988 2.6 1.392 1.084 1.4 
11 9-(methylamino 
methyl)anthracene 
(14) 13 NCP 0.988 2.8 1.517 0.792 1.7 
12 9-nitrocamptothecin (15) 13 NCP 0.985 9.2 30.320 0.563 428.4 
13 9-nitrocamptothecin (15) 13 NCP 0.982 7.8 18.770 0.551 204.7 
14 9-nitrocamptothecin (15) 13 NCP 0.992 6.4 14.810 0.567 116 
15 bovine serum albumin (16) 10 NCP 0.987 5.2 7.973 0.33 539.7 
16 bovine serum albumin (16) 10 NCP 0.963 8.1 4.560 0.322 111.3 
17 Ciprofloxacin (17) 12 NCP 0.993 8.9 32.680 1.206 18.0 
18 Ciprofloxacin HCl (18) 7 NS 0.988 21 23.487 0.871 37.5 
19 Ciprofloxacin HCl (18) 7 NS 0.999 8.5 17.210 0.86 27.4 
20 Ciprofloxacin HCl (18) 7 NS 0.982 9.5 12.680 0.631 56 
21 Ciprofloxacin HCl (18) 7 NS 0.989 13 11.320 0.735 27.2 
22 Ciprofloxacin HCl (18) 7 NS 0.997 7.8 17.220 0.828 31.1 
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Table 2. Continued… 
 
23 Ciprofloxacin HCl (18) 7 NS 0.984 12 9.843 0.618 40.5 
24 Ciprofloxacin HCl (18) 7 NS 0.994 11 10.790 0.776 21.4 
25 Cyclosporine (19) 6 NS 0.991 6.7 5.065 0.798 8.6 
26 Cyclosporine (19) 6 NS 0.982 9.4 5.177 0.754 8.9 
27 Dexamethasone 
phosphate 
(20) 5 NCP 0.993 1.6 1.548 1.211 1.4 
28 Doxorubicin (21) 8 - c 0.997 2.8 5.290 0.466 35.7 
29 Doxorubicin (21) 8            - 0.974 5.7 4.420 0.489 20.9 
30 Doxorubicin (21) 8            - 0.984 3.6 2.034 0.509 4.0 
31 Gonadorelin (22) 12 NCP 0.947 15 12.740 0.591 74.1 
32 Gonadorelin (22) 12 NCP 0.939 12 7.750 0.37 253.2 
33 Ibuprofen (23) 5 NC 0.993 4.5 10.066 0.866 14.4 
34 Ibuprofen (23) 17 NS 0.997 1.6 6.814 0.512 42.4 
35 Ibuprofen (23) 17 NS 0.978 5.8 13.039 0.628 59.7 
36 Ibuprofen (23) 17 NS 0.890 11.2 7.202 0.414 117.8 
37 Indomethacin (24) 5 NCP 0.990 5.2 0.905 1.318 0.9 
38 Indomethacin (24) 5 NCP 0.997 3.2 1.716 1.078 1.7 
39 Insulin (25) 9 NCP 0.999 1.8 53.902 1.228 25.7 
40 insulin (26) 9 NS 0.996 6.6 4.328 1.344 2.9 
41 insulin (26) 5 NS 0.999 2.9 0.024 3.076 0.3 
42 Methotrexate (27) 15 NCP 0.992 6.1 106.609 1.326 33.8 
43 Methotrexate (27) 15 NCP 0.997 3.0 8.881 0.849 13.1 
44 Methotrexate (27) 15 NCP 0.993 8.0 12.398 0.940 14.6 
45 Methotrexate (27) 15 NCP 0.977 10.0 85.297 1.367 25.9 
46 Methotrexate (27) 15 NCP 0.986 12.0 187.049 1.402 41.7 
47 Methotrexate (27) 15 NCP 0.995 7.8 9.030 0.911 11.2 
48 Methoxyxanthone (28) 8 NCP 0.984 3.5 0.546 0.729 0.4 
49 Methoxyxanthone (28) 8 NE 0.943 6.9 0.514 0.746 0.4 
50 Methylamino methyl 
anthracene 
(29) 4 NCP 0.976 5.2 0.907 1.004 0.9 
51 Methylamino methyl 
anthracene 
(29) 3 NCP 0.990 3.5 0.873 1.206 0.9 
52 Methylamino methyl 
anthracene 
(29) 7 NCP 0.998 1.2 0.763 0.762 0.7 
53 Methylamino 
methyl anthracene 
(29) 7 NCP 0.997 1.4 1.009 0.725 1.0 
54 Methylamino methyl 
anthracene 
(29) 7 NCP 0.997 1.6 0.723 0.783 0.7 
55 Methylamino methyl 
anthracene 
(29) 6 NCP 0.977 4.8 1.199 0.683 1.3 
56 Naltrexone (30) 6 NCP 0.895 3.0 1.967 0.603 3.1 
57 Naltrexone (30) 17 NCP 0.650 10.5 3.559 0.431 19.0 
58 Nifedipine (31) 14 NC 0.988 3.0 11.032 1.154 8.0 
59 Nifedipine (31) 4 NC 0.999 0.4 2.002 2.639 1.3 
60 Norfloxacin (32) 10 NS 0.971 8.6 2.694 0.999 2.7 
61 Norfloxacin (32) 10 NS 0.990 6.3 3.755 1.049 3.5 
62 Norfloxacin (32) 11 NS 0.989 6.6 5.751 0.837 8.1 
63 Norfloxacin (32) 11 NS 0.995 4.4 4.296 0.918 4.9 
64 Norfloxacin (32) 11 NS 0.989 7.0 3.982 1.133 3.4 
65 Norfloxacin (32) 11 NS 0.996 4.3 5.319 0.916 6.2 
66 paclitaxel (33) 10 NCP 0.419 19 9.645 0.31 1497 
67 paclitaxel (33) 10 NCP 0.992 4.9 49.400 0.718 228.5 
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Table 2. Continued… 
 
68 paclitaxel (33) 10 NCP 0.964 6.8 20.330 0.44 939.8 
69 paclitaxel (33) 10 NCP 0.968 6.9 10.220 0.368 553.4 
70 paclitaxel (33) 10 NCP 0.961 7.5 10.953 0.374 601.9 
71 paclitaxel (33) 10 NCP 0.95 6.7 9.360 0.307 1458 
72 Papaverine 
hydrochloride 
(34) 17 NS 0.979 10.6 1222.84 5.050 4.1 
73 Papaverine 
hydrochloride 
(34) 17 NS 0.944 8.5 11.187 1.211 7.3 
74 Papaverine 
hydrochloride 
(34) 16 NS 0.980 22.1 26.666 1.345 11.5 
75 Papaverine 
hydrochloride 
(34) 17 NS 0.970 17.4 15.855 0.963 17.6 
76 Praziquantel (35) 11 NS 0.958 7.8 36.593 0.723 145.3 
77 Praziquantel (35) 5 NS 0.998 4.3 169.55 0.779 727.3 
78 Prednisone (36) 5 NS 0.989 7.1 15.069 0.705 46.9 
79 Prednisone (36) 9 NS 0.907 13.0 6.618 0.348 228.2 
80 Procaine (37) 6 NS 0.992 1.2 0.099 1.161 0.1 
81 progesterone (38) 7 NS 0.978 3.9 3.516 0.342 4.1 
82 progesterone (38) 7 NS 0.989 2.9 3.460 0.287 75.6 
83 progesterone (38) 7 NS 0.999 1.3 2.037 0.58 3.4 
84 progesterone (38) 7 NS 0.969 3.1 0.811 0.471 0.6 
85 progesterone (38) 7 NS 0.955 2.2 0.421 0.906 0.4 
86 progesterone (38) 5 NS 0.994 3.19 1.987 0.498 4.0 
87 progesterone (38) 7 NS 0.846 13 1.965 0.421 5.0 
88 progesterone (38) 7 NS 0.965 9.5 0.580 0.535 0.4 
89 propafenone (39) 8 NCP 0.996 1.4 9.360 0.468 118.9 
90 propafenone (39) 8 NCP 0.984 3.6 16.703 0.612 99.5 
91 propafenone (39) 8 NCP 0.977 3.5 14.405 0.615 76.5 
92 propafenone (39) 8 NCP 0.955 6.2 13.296 0.645 55.2 
93 propafenone (39) 8 NCP 0.967 5 19.536 0.766 48.4 
94 propafenone (39) 8 NCP 0.97 4.8 17.589 0.774 40.6 
95 propafenone (39) 8 NCP 0.952 4.3 15.550 0.55 146.8 
96 propafenone (39) 8 NCP 0.976 4.2 18.617 0.624 108.4 
97 propafenone (39) 8 NCP 0.996 2.1 24.729 0.727 82.5 
98 propafenone (39) 8 NCP 0.996 2 19.059 0.672 80.3 
99 propafenone (39) 7 NCP 0.984 3.1 16.716 0.762 40.3 
100 Savoxepine (40) 12 NS 0.978 6.7 24.414 0.506 552.5 
101 Silk peptide (41) 6 NCP 0.869 4.1 4.553 1.174 3.6 
102 Silk peptide (41) 15 NCP 0.865 10.0 5.328 0.549 21.1 
103 Tamoxifen (42) 9 NCP 0.997 3.9 8.503 0.818 13.7 
104 Tripentone (43) 10 NCP 0.997 23 229.90 1.391 49.9 
105 Xanthone (28) 6 NE 0.924 4.0 0.422 0.550 0.2 
106 Xanthone (28) 6 NCP 0.752 9.2 0.681 0.380 0.4 
 
a N is number of data in each set. b NS, NCP, NC and NE stand for nanosphere, nanocapsule, nanocrystal and nonoemulsion. 
c The type of nanosystem was not specified in the original paper.  d t50% was calculated by t50% = m 1/b. 
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DISCUSSION 
 
Kinetic study of drug release is often useful in 
obtaining one or two physically meaningful 
parameters which are employed for comparative 
purposes and relating the release parameter with 
important parameters such as bioavailability. 
Furthermore a kinetic parameter can be used to 
study the influence of formulation factors on the 
drug release for optimization as well as control of 
release. The models having both single figure 
overall error (OE) and number of single figure OEs 
higher than 75% of total number of sets were 
considered as suitable general models. According to 
Table 1 the models met this criterion are Weibull 
(W), reciprocal powered time (RPT) and Wagner’s 
log- probability (LP) models with the OE values of 
6.39, 6.47 and 6.77, respectively. From OE point of 
view our RPT model is comparable with W but 
these two are slightly superior to LP model. With 
respect to number of errors less than 5, 10 and 12 % 
the RPT model is superior to the other two ones. 
For example the corresponding NEs less than 10% 
for the RPT, W and LP models are 84.9, 80.2 and 
78.3 (Table 1). The maximum error not shown in 
the table associated with the RPT model is 23.0% 
which is less than that of W model (24.3%) but 
higher that of LP model (19.4%). Regarding the 
mentioned criteria it can be said that overall 
proposed RPT model can be considered as a general 
model for drug release kinetics from nanosystems. 
The advantage of the model over other models is 
the fact that from its parameters, b and m, the most 
meaningful release parameter release half life (t50%) 
i.e., time required for 50% of drug to be released, 
can be calculated from t50% = m1/b. This relationship 
is readily obtained by substitution of 0.5 for F, t50% 
for t into the model (equation 13 in Table 1) and 
subsequent solution for t50%. The release half life is 
conversely related to release rate. The parameters of 
RPT model together with t50% for 106 formulations 
examined are seen in Table 2.  
 
Theoretical justifications for the best models: 
Reciprocal powered time model   
 
The rate of drug release from any solid or semi 
solid delivery system is usually controlled by 
dissolution and/or diffusion. Regardless of 
mechanisms involved in the release, its rate under 
sink conditions can be expressed by a single general 
equation as follows: 
 
  (3) 
 
w is amount of drug released up to time t and dw/dt 
is the rate of release. D, S, Cs and h are drug 
molecule diffusion coefficient, effective surface 
area of drug with release medium, drug solubility in 
the medium and the length of diffusion path. This 
equation represents both the Noyes-Whitney law of 
dissolution (44) applied for dissolution rate limited 
release as well as the Fick’s first law of diffusion 
used for diffusion rate limited release processes 
(45,46). In the dissolution process h, the thickness 
of stagnant aqueous layer around drug particle, is 
constant but S and sometimes D are varied during 
the release process (47). On the other hand in a 
diffusion rate limited release in addition to D, h and 
sometimes S are variable during the release process. 
For a complex system such as nanoparticles 
equation 3 does not seem to include all other factors 
influencing the release rate among which 
penetration rate of liquid into the system; hydration, 
swelling, relaxation, erosion and dissolution of 
polymer can be mentioned. The extents of liquid 
penetration and the polymer contributed properties 
are directly proportional to t1/2 (48) and powered of t 
(49-52), respectively. Thus, these effects are 
collectively represented as a time dependent 
variable, X, and equation 3 becomes: 
 
  (4) 
 
Therefore, regardless of release mechanism in order 
to obtain a general working formula for both 
dissolution and diffusion rate limited release 
processes it is assumed that the term DSX/h is 
variable during the release. The integration of 
equation 4 between time 0 and t as well as 0 and ∞ 
yields:  
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  (5) 
 
 (6) 
 
Where w∞ is the total amount of drug released in the medium. The amount of drug remaining to be released, M, 
is given by: 
 
  (7) 
 
Fraction of drug released, F, at any time is calculated by: 
 
 (8) 
 
 
 
Since, the value of is increasing with 
time whereas the opposite is true for , 
it is reasonable to assume that the respective 
integrals are expressed by the power terms in the 
forms of α ta and α' t-a' . Where α, a, α' and a' are 
constants. Substitution of the power equations into 
the far-right side of equation 8 results in: 
 
   (9) 
 
In which b = a + a' and m = α'/α. Reciprocating the 
far right side of equation 9 and subsequent 
rearrangements would yield the reciprocal powered 
time model. Equation 9 is similar to previously 
published model applied for a simpler solid 
dispersion systems (11). In the derivation leading to 
that model only the effective surface area of the 
drug was assumed to be variable and hence the 
release mechanism was dissolution rate limited 
solely. The present equation, however, is extended 
the application of reciprocal powered time model to 
both dissolution and diffusion rate limited processes 
and thus is considered to be a general release 
equation.   
 
The Weibull model 
 
This is an empirical model which has been widely 
applied to release data of both rapid and extended 
release drug delivery systems(53-63). If it is 
assumed that some of the factors influencing the 
overall drug release e.g. effective surface area (S) 
are solely mass dependent, mass of unreleased drug 
in the medium (8), while the others are considered 
to be time dependent, thus equation 4 can be written 
as:  
 
  (10) 
 
Where kM = S and k'tp = X. According to 
previously published papers  (47) as well 
as  (45,46),  inclusion of theses in to 
equation 10 and converting the amounts in to 
fractions in the subsequent equation yields the 
following relationship: 
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  (11) 
 
In which F = w/w∞, (1-F) = M/ w∞, w∞ is total 
amount of drug ultimately released and q includes 
n, n' and p. The value of kb is related to Cs and other 
constants. Rearrangement of equation 11 gives 
equation 12:  
 
  (12) 
 
The integration of equation 12 between times 0 and 
t yields:  
 
  (13) 
 
The latter equation can be written as the linear form 
of Weibull distribution: 
 
   ln[-ln(1-F)]= lnkw+βlnt                                                                                                           
    
   In which kw =  kb/(q+1), β = q+1 and kw=(1/td)β. 
 
The derivation here is different from the one 
provided previously (47) in which constant drug 
effective surface area and non sink conditions were 
assumed.  
 
CONCLUSION 
 
Evaluation of 13 kinetic models for drug release 
from nanoparticles indicated that three models i.e. 
the novel reciprocal powered time, Weibull and 
Wagner’s log-probability models were superior to 
the rest of models in that the errors associated with 
those were single figures and the number of single 
figure errors was higher than other models. Among 
the three mentioned models, the reciprocal powered 
time model was more suitable than the other two 
ones considering the accuracy criteria used for 
comparison. In addition to the mentioned 
superiority of reciprocal powered time model, from 
its parameters a fundamental parameter i.e., release 
half life can be calculated which is a most widely 
used criterion for comparison of drug release rate. 
Taking into account complex processes involved in 
drug release from nanosystems, theoretical 
justifications for the reciprocal powered time as 
well as Weibull models were provided. Based on 
the theoretical justifications, the reciprocal powered 
time and Weibull models seem to be applicable for 
any drug release mechanisms involving dissolution, 
diffusion and mixed dissolution - diffusion rate 
limited processes.  
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